Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Molecular Diagnosis & Therapy
Erschienen in: Molecular Diagnosis & Therapy 5/2018

01.10.2018 | Current Opinion

Alzheimer’s Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing

verfasst von: Jill S. Goldman, Vivianna M. Van Deerlin

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

The advent of next-generation sequencing has changed genetic diagnostics, allowing clinicians to test concurrently for phenotypically overlapping conditions such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). However, to interpret genetic results, clinicians require an understanding of the benefits and limitations of different genetic technologies, such as the inability to detect large repeat expansions in such diseases as C9orf72-associated FTD and amyotrophic lateral sclerosis. Other types of mutations such as large deletions or duplications and triple repeat expansions may also go undetected. Additionally, the concurrent testing of multiple genes or the whole exome increases the likelihood of discovering variants of unknown significance. Our goal here is to review the current knowledge about the genetics of AD and FTD and suggest up-to-date guidelines for genetic testing for these dementias. Despite the improvements in diagnosis due to biomarkers testing, AD and FTD can have overlapping symptoms. When used appropriately, genetic testing can elucidate the diagnosis and specific etiology of the disease, as well as provide information for the family and determine eligibility for clinical trials. Prior to ordering genetic testing, clinicians must determine the appropriate genes to test, the types of mutations that occur in these genes, and the best type of genetic test to use. Without this analysis, interpretation of genetic results will be difficult. Patients should be counseled about the benefits and limitations of different types of genetic tests so they can make an informed decision about testing.
Literatur
1.
Jarmolowicz AI, Chen HY, Panegyres PK. The patterns of inheritance in early-onset dementia: Alzheimer’s disease and frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2014;30(3):299–306.CrossRefPubMed
2.
Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2012;69(1):59–64.CrossRefPubMed
3.
4.
Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253–60.CrossRefPubMedPubMedCentral
5.
6.
Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement. 2016;12(6):733–48.CrossRefPubMed
7.
Larner AJ. Presenilin-1 mutations in Alzheimer’s disease: an update on genotype-phenotype relationships. J Alzheimers Dis. 2013;37(4):653–9.CrossRefPubMed
8.
9.
10.
Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011;13(6):597–605.CrossRefPubMedPubMedCentral
11.
Van den Bossche T, Sleegers K, Cuyvers E, Engelborghs S, Sieben A, De Roeck A, et al. Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation. Neurology. 2016;86(23):2126–33.CrossRefPubMedPubMedCentral
12.
Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4, and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013;309(14):1483–92.CrossRefPubMedPubMedCentral
13.
Vardarajan BN, Ghani M, Kahn A, Sheikh S, Sato C, Barral S, et al. Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci. Ann Neurol. 2015;78(3):487–98.CrossRefPubMedPubMedCentral
14.
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–27.CrossRefPubMed
15.
16.
Tosto G, Reitz C. Genomics of Alzheimer’s disease: value of high-throughput genomic technologies to dissect its etiology. Mol Cell Probes. 2016;30(6):397–403.CrossRefPubMed
17.
Piccoli E, Rossi G, Rossi T, Pelliccioni G, D’Amato I, Tagliavini F, et al. Novel PSEN1 mutations (H214N and R220P) associated with familial Alzheimer’s disease identified by targeted exome sequencing. Neurobiol Aging. 2016;40(192):e7–11.
18.
van Duijn CM, Cruts M, Theuns J, Van Gassen G, Backhovens H, van den Broeck M, et al. Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer’s disease in a population-based sample. Eur J Hum Genet. 1999;7(7):801–6.
19.
Lambert JC, Mann DM, Harris JM, Chartier-Harlin MC, Cumming A, Coates J, et al. The −48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer’s disease and an increased Abeta load in brain. J Med Genet. 2001;38(6):353–5.CrossRefPubMedPubMedCentral
20.
Theuns J, Remacle J, Killick R, Corsmit E, Vennekens K, Huylebroeck D, et al. Alzheimer-associated C allele of the promoter polymorphism −22C > T causes a critical neuron-specific decrease of presenilin 1 expression. Hum Mol Genet. 2003;12(8):869–77.CrossRefPubMed
21.
Cuccaro D, De Marco EV, Cittadella R, Cavallaro S. Copy number variants in Alzheimer’s disease. J Alzheimers Dis. 2017;55(1):37–52.CrossRefPubMed
22.
Hogan DB, Jette N, Fiest KM, Roberts JI, Pearson D, Smith EE, et al. The prevalence and incidence of frontotemporal dementia: a systematic review. Can J Neurol Sci. 2016;43(Suppl 1):S96–109.CrossRefPubMed
23.
Mackenzie IR, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem. 2016;138(Suppl 1):54–70.CrossRefPubMed
24.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456–77.CrossRefPubMedPubMedCentral
25.
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–14.CrossRefPubMedPubMedCentral
26.
Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem. 2016;138(Suppl 1):32–53.CrossRefPubMed
27.
Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40(5):572–4.CrossRefPubMed
28.
Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36(4):377–81.CrossRefPubMed
29.
Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet. 2005;37(8):806–8.CrossRefPubMed
30.
Olszewska DA, Lonergan R, Fallon EM, Lynch T. Genetics of frontotemporal dementia. Curr Neurol Neurosci Rep. 2016;16(12):107.CrossRefPubMed
31.
Munch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Krause BJ, et al. Heterozygous R1101 K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol. 2005;58(5):777–80.CrossRefPubMed
32.
Fecto F, Siddique T. Making connections: pathology and genetics link amyotrophic lateral sclerosis with frontotemporal lobe dementia. J Mol Neurosci. 2011;45(3):663–75.CrossRefPubMed
33.
Borroni B, Padovani A. Dementia: a new algorithm for molecular diagnostics in FTLD. Nat Rev Neurol. 2013;9(5):241–2.CrossRefPubMed
34.
Gellera C, Tiloca C, Del Bo R, Corrado L, Pensato V, Agostini J, et al. Ubiquilin 2 mutations in Italian patients with amyotrophic lateral sclerosis and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2013;84(2):183–7.CrossRefPubMed
35.
Bannwarth S, Ait-El-Mkadem S, Chaussenot A, Genin EC, Lacas-Gervais S, Fragaki K, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137(Pt 8):2329–45.CrossRefPubMedPubMedCentral
36.
Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Philtjens S, Heeman B, et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology. 2015;85(24):2116–25.CrossRefPubMedPubMedCentral
37.
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393(6686):702–5.CrossRefPubMed
38.
Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, et al. Evidence for a role of the rare p. A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer’s diseases. Hum Mol Genet. 2012;21(15):3500–12.CrossRefPubMedPubMedCentral
39.
Labbe C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Rayaprolu S, et al. Role for the microtubule-associated protein tau variant p. A152T in risk of alpha-synucleinopathies. Neurology. 2015;85(19):1680–6.CrossRefPubMedPubMedCentral
40.
41.
Van Deerlin VM, Forman MS, Farmer JM, Grossman M, Joyce S, Crowe A, et al. Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual. Acta Neuropathol. 2007;113(4):471–9.CrossRefPubMed
42.
Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442(7105):920–4.CrossRefPubMed
43.
Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916–9.CrossRefPubMed
44.
Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry. 2013;84(9):956–62.CrossRefPubMed
45.
Miller ZA, Sturm VE, Camsari GB, Karydas A, Yokoyama JS, Grinberg LT, et al. Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: completing the picture. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e301.CrossRefPubMedPubMedCentral
46.
Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129(4):469–91.CrossRefPubMed
47.
Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 2013;36(8):450–9.CrossRefPubMed
48.
Cooper-Knock J, Shaw PJ, Kirby J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 2014;127(3):333–45.CrossRefPubMedPubMedCentral
49.
Hall D, Finger EC. Psychotic symptoms in frontotemporal dementia. Curr Neurol Neurosci Rep. 2015;15(7):46.CrossRefPubMed
50.
Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol. 2015;14(3):291–301.CrossRefPubMed
51.
Suh E, Lee EB, Neal D, Wood EM, Toledo JB, Rennert L, et al. Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol. 2015;130(3):363–72.CrossRefPubMedPubMedCentral
52.
Bocchetta M, Cardoso MJ, Cash DM, Ourselin S, Warren JD, Rohrer JD. Patterns of regional cerebellar atrophy in genetic frontotemporal dementia. Neuroimage Clin. 2016;11:287–90.CrossRefPubMedPubMedCentral
53.
Gomez-Tortosa E, Gallego J, Guerrero-Lopez R, Marcos A, Gil-Neciga E, Sainz MJ, et al. C9ORF72 hexanucleotide expansions of 20–22 repeats are associated with frontotemporal deterioration. Neurology. 2013;80(4):366–70.CrossRefPubMed
54.
Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet. 2013;92(3):345–53.CrossRefPubMedPubMedCentral
55.
Rutherford NJ, Heckman MG, Dejesus-Hernandez M, Baker MC, Soto-Ortolaza AI, Rayaprolu S, et al. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging. 2012;33(12):2950 e5–7.
56.
van Blitterswijk M, Baker MC, DeJesus-Hernandez M, Ghidoni R, Benussi L, Finger E, et al. C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology. 2013;81(15):1332–41.CrossRefPubMedPubMedCentral
57.
Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, De Bleecker J, et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol Psychiatry. 2016;21(8):1112–24.CrossRefPubMed
58.
Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42(3):234–9.CrossRefPubMedPubMedCentral
59.
60.
Chen Y, Li S, Su L, Sheng J, Lv W, Chen G, et al. Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. J Neurol. 2015;262(4):814–22.CrossRefPubMed
61.
Kara E, Ling H, Pittman AM, Shaw K, de Silva R, Simone R, et al. The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging. 2012;33(9):2231 e7–e14.
62.
Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet. 2012;90(6):1102–7.CrossRefPubMedPubMedCentral
63.
van der Zee J, Gijselinck I, Van Mossevelde S, Perrone F, Dillen L, Heeman B, et al. TBK1 mutation spectrum in an extended European patient cohort with frontotemporal dementia and amyotrophic lateral sclerosis. Hum Mutat. 2017;38(3):297–309.CrossRefPubMedPubMedCentral
64.
Kovacs GG, van der Zee J, Hort J, Kristoferitsch W, Leitha T, Hoftberger R, et al. Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia. Neuropathology. 2016;36(1):27–38.CrossRefPubMed
65.
Wood EM, Falcone D, Suh E, Irwin DJ, Chen-Plotkin AS, Lee EB, et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. 2013;70(11):1411–7.CrossRefPubMedPubMedCentral
66.
Van Deerlin VM. The genetics and neuropathology of neurodegenerative disorders: perspectives and implications for research and clinical practice. Acta Neuropathol. 2012;124(3):297–303.CrossRefPubMedPubMedCentral
67.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–23.CrossRefPubMedPubMedCentral
68.
Almeida MR, Letra L, Pires P, Santos A, Rebelo O, Guerreiro R, et al. Characterization of an FTLD-PDB family with the coexistence of SQSTM1 mutation and hexanucleotide (G(4)C(2)) repeat expansion in C9orf72 gene. Neurobiol Aging. 2016;40(191):e1–8.
69.
Origone P, Accardo J, Verdiani S, Lamp M, Arnaldi D, Bellone E, et al. Neuroimaging features in C9orf72 and TARDBP double mutation with FTD phenotype. Neurocase. 2014;20:1–6.CrossRef
70.
Sha SJ, Khazenzon AM, Ghosh PM, Rankin KP, Pribadi M, Coppola G, et al. Early-onset Alzheimer’s disease versus frontotemporal dementia: resolution with genetic diagnoses? Neurocase. 2016;22(2):161–7.CrossRefPubMed
71.
Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323–30.CrossRefPubMedPubMedCentral
72.
Goldman JS, Farmer JM, Wood EM, Johnson JK, Boxer A, Neuhaus J, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65(11):1817–9.CrossRefPubMed
73.
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–3.CrossRefPubMed
Metadaten
Titel
Alzheimer’s Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing
verfasst von
Jill S. Goldman
Vivianna M. Van Deerlin
Publikationsdatum
01.10.2018
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 5/2018
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-018-0347-7

Weitere Artikel der Ausgabe 5/2018

Molecular Diagnosis & Therapy 5/2018 Zur Ausgabe

Original Research Article

Molecular Detection of Streptococcus pyogenes by Strand Invasion Based Amplification Assay

Systematic Review

The Role of E-Cadherin as a Prognostic Biomarker in Head and Neck Squamous Carcinoma: A Systematic Review and Meta-Analysis

Original Research Article

Validation Strategy for Ultrasensitive Mutation Detection

Review Article

Biomarkers and Pharmacogenomics in Kidney Transplantation

Review Article

Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs

Current Opinion

Cell-Free eccDNAs: A New Type of Nucleic Acid Component for Liquid Biopsy?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise